Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01849276 · ClinicalTrials.gov registry record · Phase 1
Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML
A Phase 1 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT01849276 is a Phase 1 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 2 participants.
The verdict
NCT01849276, a Phase 1 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of the study is to determine if metformin in combination with cytarabine is safe and effective. Participants in this research study have acute myeloid leukemia (AML) that has come back after initial treatment or has not gone away with initial therapy.There is evidence that metformin directly kills leukemia cells. Laboratory data have also shown that combinations of metformin with cytarabine are more efficient than each agent alone in killing leukemia cells in the laboratory.
Interventions
- OTHER laboratory biomarker analysis
- DRUG metformin hydrochloride
- DRUG cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-03-11 |
| Est. Completion | 2016-01-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01849276
The ClinicalTrials.gov registry entry for NCT01849276 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01849276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01849276 about?
NCT01849276 is a clinical study titled "Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML". The purpose of the study is to determine if metformin in combination with cytarabine is safe and effective. Participants in this research study have acute myeloid leukemia (AML) that has come back after initial treatment or has not gone away with initial therapy.There is evidence that metformin dire...
What is the current status of trial NCT01849276?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2015-03-11. Estimated completion is 2016-01-21.
What interventions are being tested in trial NCT01849276?
The interventions under investigation include: laboratory biomarker analysis (OTHER), metformin hydrochloride (DRUG), cytarabine (DRUG).
Who is sponsoring clinical trial NCT01849276?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.